Lexington, Massachusetts-based uniQure N.V. (Nasdaq: QURE) announced the pricing of an upsized underwritten public offering of ordinary shares, raising USD 225 million in gross proceeds to fund the regulatory filing and continued clinical development of its lead Huntington's disease gene therapy, AMT-130. The uniQure public offering was upsized from an initial USD 150 million target announced two days earlier, a 50% increase that reflects institutional demand following a material improvement in the program's regulatory outlook.
The offering comprised 4,945,055 ordinary shares priced at USD 45.50 per share, with all securities sold by uniQure. Underwriters were granted a 30-day option to purchase up to an additional 741,758 shares at the same price. Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets acted as joint bookrunning managers; H.C. Wainwright & Co. served as lead manager. The offering was expected to close on or about June 25, 2026, subject to customary closing conditions. No specific use of proceeds breakdown was disclosed beyond general clinical development and corporate purposes.
Company overview and pipeline
uniQure is a gene therapy company focused on neurological and rare genetic diseases. Its only approved product, the hemophilia B gene therapy Hemgenix (etranacogene dezaparvovec), is commercialized by CSL Behring under a licensing agreement, leaving AMT-130 as the company's primary wholly owned commercial opportunity.
The financing comes shortly after uniQure disclosed that the US FDA indicated three-year Phase I/II data for AMT-130 could support an accelerated approval filing — a development that materially clarified the regulatory pathway and directly preceded the offering launch. AMT-130 is an AAV5-based gene therapy for Huntington's disease that delivers a microRNA designed to reduce mutant huntingtin protein expression. High-dose AMT-130 demonstrated a statistically significant 75% slowing of disease progression versus a propensity score-matched external control cohort in three-year follow-up analyses. uniQure has indicated plans to submit a Biologics License Application in Q3 2026, with a UK regulatory submission also targeted for Q3 2026.